For decades, menopause was discussed largely through the language of hot flashes, irregular periods, mood changes, sleep disruption, and fertility decline. But a growing body of cardiovascular research is reframing the years before menopause as something far more consequential: an early warning period for women’s heart health.
The message from recent medical evidence is clear. Perimenopause should not be treated as a waiting room before menopause. It should be treated as a cardiovascular checkpoint.
A May 2026 analysis published through the American Heart Association reported that perimenopause may offer a “window of opportunity” for heart disease prevention. The study, based on a nationwide U.S. population dataset, found that women in perimenopause were more likely to show lower cardiovascular health scores than women with regular menstrual cycles, particularly in cholesterol and blood sugar measures.
“Perimenopause is not just a hormonal transition. It is a metabolic transition, and for many women, the first signs of future cardiovascular risk begin to appear here.”
The timing matters because cardiovascular disease remains the leading cause of death among women. The CDC states that heart disease is the leading cause of death for women in the United States, with more than 60 million women living with some form of heart disease. In 2023, heart disease was responsible for 304,970 female deaths in the U.S., roughly one in every five female deaths.
Globally, the burden is equally serious. The World Heart Federation says cardiovascular disease is responsible for around 30% of deaths in women each year and remains under-recognised, under-diagnosed, and under-treated in women.
The Heart Risk Hidden Inside the Menopause Transition
Perimenopause usually begins in the 40s, though it can start earlier. During this phase, estrogen levels fluctuate before eventually declining. That hormonal shift does not act in isolation. It can interact with blood vessels, cholesterol metabolism, insulin sensitivity, body fat distribution, sleep quality, inflammation, and blood pressure.
Research reviews have consistently linked the menopause transition with cardiometabolic changes, including increased blood pressure, adverse lipid changes, insulin resistance, and shifts in body composition. A 2024 review noted that cardiovascular disease risk notably increases in the fifth decade of a woman’s life, coinciding with the onset of menopause.
This is why many physicians now argue that the old model — waiting until after menopause to look seriously at heart risk — is too late.
“By the time symptoms become obvious, the risk factors may have been building silently for years. The smarter strategy is to screen while the risk curve is still bendable.”
The American Heart Association’s 2026 report on future cardiovascular burden also raised a wider warning: nearly six in ten U.S. women are projected to have at least one type of cardiovascular disease by 2050, driven in part by rising hypertension, diabetes, and obesity.
Why Traditional Risk Calculators May Miss Women
One of the most important debates in women’s heart health is whether standard cardiovascular risk tools fully capture female-specific risk. Many tools focus heavily on age, cholesterol, blood pressure, diabetes, and smoking. Those are essential, but they may miss reproductive and hormonal history.
Women with premature menopause — menopause before age 40 — appear to face higher lifetime coronary heart disease risk. A 2026 report discussing JAMA Cardiology findings noted that premature menopause was associated with about a 40% increased risk of fatal and nonfatal myocardial infarction compared with later menopause.
Adverse pregnancy outcomes also matter. The American Heart Association has highlighted that conditions such as hypertensive disorders of pregnancy, gestational diabetes, preterm delivery, and other adverse pregnancy outcomes are significant risk factors for future heart disease, heart failure, stroke, chronic kidney disease, and vascular dementia.
The American College of Cardiology has also warned that adverse pregnancy outcomes are treated as “risk enhancers,” but they are not always included directly in common risk calculators.
That gap is important. A woman may be told she has “low risk” because she is not yet old enough to score high on a traditional calculator, even though her reproductive history, rising blood pressure, worsening cholesterol, abdominal weight gain, or gestational diabetes history tells a different story.
“For midlife women, cardiovascular screening must ask more than: What is your cholesterol? It must also ask: What happened during pregnancy? When did your cycles change? When did menopause begin? What has changed in sleep, weight, blood pressure, and glucose?”
What Earlier Screening Should Include
Earlier screening does not mean panic. It means creating a baseline before risk becomes disease.
For women entering their 40s — and especially those with irregular periods, vasomotor symptoms, weight gain, family history, high blood pressure, prior gestational diabetes, preeclampsia, premature menopause, PCOS, autoimmune disease, or smoking history — clinicians increasingly recommend a more proactive cardiovascular review.
A practical perimenopause heart-health screening conversation should include:
Blood pressure: checked regularly, not only during illness or clinic visits.
Lipid profile: LDL, HDL, triglycerides, and total cholesterol.
Blood sugar health: fasting glucose or HbA1c, especially with weight gain or prior gestational diabetes.
Weight and waist circumference: because midlife fat redistribution can increase cardiometabolic risk.
Family history: early heart attack, stroke, diabetes, or high cholesterol.
Reproductive history: premature menopause, early menopause, pregnancy complications, PCOS, fertility treatment history, and hysterectomy or oophorectomy.
Lifestyle risk: sleep, stress, physical activity, alcohol, smoking, diet quality, and sedentary time.
Advanced markers where appropriate: lipoprotein(a), high-sensitivity C-reactive protein, and coronary artery calcium scoring may be considered based on clinician judgment and risk profile.
A Reuters-reported 2024 cardiovascular study also drew attention to the value of earlier blood-based risk estimation in women, including LDL cholesterol, high-sensitivity C-reactive protein, and lipoprotein(a), suggesting that risk evaluation may need to begin much earlier than the postmenopausal years for many women.
Lifestyle Is Still the First Prescription
The most powerful message is not that perimenopause guarantees heart disease. It does not. The stronger message is that this stage offers an opportunity to intervene.
The American Heart Association’s Life’s Essential 8 framework focuses on diet, physical activity, nicotine exposure, sleep, body weight, cholesterol, blood sugar, and blood pressure. The 2026 perimenopause analysis used this framework and found that cardiovascular health scores worsened across the menopausal transition, reinforcing the need to act earlier.
The World Heart Federation also notes that many heart attacks and strokes are preventable because major risk factors such as high blood pressure, high cholesterol, obesity, diabetes, tobacco use, unhealthy diet, and physical inactivity can often be controlled or improved.
For midlife women, that prevention plan is not glamorous, but it is powerful: strength training, regular aerobic activity, adequate protein and fiber, lower ultra-processed food intake, better sleep, blood pressure monitoring, glucose control, stress management, and smoking cessation.
“The goal is not to medicalize midlife. The goal is to stop dismissing midlife symptoms as ‘normal’ when they may be the first visible edge of cardiovascular risk.”
The HRT Question: Helpful, But Not a Heart-Disease Shortcut
Menopausal hormone therapy can be appropriate for selected women with bothersome menopausal symptoms, but it should not be marketed as a universal heart-disease prevention strategy. Current medical discussions emphasize individualized decision-making based on age, timing since menopause, symptoms, personal risk factors, and contraindications.
The American Medical Association’s 2025 discussion on menopause and cardiovascular disease highlighted the importance of timing and individualized care when considering hormone therapy for peri- and postmenopausal symptoms.
For women with high cardiovascular risk, prior clotting events, stroke, certain cancers, uncontrolled hypertension, or complex medical histories, treatment decisions need careful medical review.
A New Standard for Women’s Preventive Care
The broader shift is cultural as much as clinical. Women’s cardiovascular symptoms and risk factors have too often been minimized, delayed, or misattributed to stress, aging, anxiety, or hormones. But the latest evidence suggests that hormones and heart risk are not separate conversations.
They are connected.
Perimenopause should become a standard trigger for cardiovascular risk reassessment, the same way pregnancy history should follow a woman into long-term preventive care. The annual health check for a woman in her 40s should not stop at thyroid tests, vitamin D, mammograms, and gynecological review. It should include a serious heart-health baseline.
For health systems, insurers, employers, and clinicians, the opportunity is clear: earlier screening can identify risk when it is still modifiable. For women, the message is equally direct: do not wait for chest pain to start caring about the heart.
Perimenopause is not the end of youth. It may be the beginning of a more intelligent, data-driven phase of preventive health.
“The women who benefit most from heart screening may not be the women who already look sick. They may be the women who are busy, functional, tired, gaining weight, sleeping poorly, and being told everything is just part of aging.”
